Last updated: April 24, 2026
Japan drug patent JP2019199485: scope, claim positioning, and landscape
What is JP2019199485 and what does it cover?
JP2019199485 is a Japan patent publication filed in the 2019 publication cycle and published under the JP publication format “JP2019-199485.” The publication number indicates a Japan patent application rather than a granted patent, so the controlling “scope” for business decisions is the set of claims in the published application and any claim amendments during prosecution.
However, the record details required to produce a complete and accurate scope-and-claims breakdown (exact title, applicant/assignee, earliest priority, claim set, claim dependencies, and the claimed compound(s)/formulation(s)) are not present in the information provided in this thread. Without those specifics, a precise claim chart, ingredient-level or use-level claim mapping, and an accurate landscape crosswalk against relevant Japanese and global families would risk being wrong.
What is the claim scope in JP2019199485?
A proper scope analysis requires the exact wording of the claims, including:
- independent claim(s) covering the active ingredient (compound or salt), composition, and/or method of treatment
- dependent claim coverage (specific embodiments, particle size, polymorphs, formulation excipients, dosages, administration routes)
- any claim-limited definitions (terms like “pharmaceutical composition,” “therapeutically effective amount,” “wherein R is…,” or “for use in treating…”)
Those claim texts are not available in the provided inputs, so a complete and accurate claim-scope reconstruction cannot be produced.
How does JP2019199485 position relative to common Japanese pharma claim types?
Japanese filings for small-molecule drugs and biologics typically cluster into a few claim families. A correct landscape analysis must test whether JP2019199485 is:
- a compound patent (structure and analog series)
- a composition/formulation patent (salt, polymorph, crystalline form, solid dispersion, sustained-release matrix, excipients)
- a method-of-treatment patent (indication, dosing regimen, combination therapy)
- a use patent (second medical use) depending on claim format in Japan prosecution practice
No claim text is provided, so the correct category and its boundaries cannot be determined.
What is the patent landscape for JP2019199485 in Japan?
A landscape for a Japan publication requires:
- identification of the full family (priority application(s), PCT, US/EU/other counterparts)
- active status and claim breadth in Japan (publication date, application number, examination status, grant/rejection outcomes if available)
- citations and legal-event mapping (office actions, amendments, and cited prior art)
- freedom-to-operate adjacency: other JP publications and grants on (1) the same active ingredient, (2) same salt/polymorph/formulation, and (3) same indication and regimen, plus combination patents
Those inputs are not available here. Producing a landscape without verifying family membership and claim overlap would not meet the “hard data” standard for investment or R&D decisions.
Where does JP2019199485 sit versus global families?
A credible global comparison also requires:
- the earliest priority and the underlying chemical series or biological target
- the CPC/IPC classification for JP2019199485
- matching to corresponding WO, EP, US publications
- checking if JP claim strategy tracks the global set or diverges (common in Japan with formulation and use claim narrowing)
No priority data, CPC/IPC codes, or family links are provided, so a defensible global positioning cannot be built.
What “scope levers” must be verified for JP2019199485?
To determine the real enforceability and likely validity, the following must be confirmed directly from the patent document:
- Definition of active: compound formula vs salt vs polymorph vs formulation-specific characterization
- Structure breadth: variable groups, Markush scope, stereochemistry and solvate/polymorph constraints
- Functional limitations: binding activity thresholds, inhibitory concentration ranges, or pharmacokinetic constraints
- Therapeutic limitations: disease/indication, patient subgroup, biomarker requirement
- Combination constraints: co-administered drugs (exact names vs classes)
- Dosing/route: mg ranges, dosing frequency, duration, oral vs injectable
- Exemption-risk features: claims that overlap with known generics via generic process or known formulation defaults
None of these claim-lever details are present in the provided inputs.
Key Takeaways
- JP2019199485 cannot be analyzed for scope and claim boundaries without the actual claim text and bibliographic record (title, applicant, priority, and claim set).
- A defensible Japan and global patent landscape requires family membership, CPC/IPC codes, legal status, and citation mapping, none of which are available in the provided inputs.
- With the required document elements missing, producing an “actionable” claim chart or landscape adjacency would not meet the accuracy requirement for high-stakes R&D or investment work.
FAQs
-
Is JP2019199485 a granted patent or an application publication?
JP numbering in the 2019 publication format typically indicates a published application; confirming grant status requires the bibliographic/legal status record, which is not provided here.
-
What defines “scope” for JP drug patents in Japan?
The issued or published claim wording defines scope, including independent claims and dependent claim limitations.
-
How is a Japan drug landscape built from a single JP publication?
By mapping the document to its family (priority/WOs) and enumerating overlapping JP filings on the same compound/formulation/use.
-
What parts of claims most affect enforceability?
Claim definitions (compound/salt/polymorph), structural breadth, indication or method-of-treatment limits, and any combination/dosing constraints.
-
Can a landscape be produced without claim text?
A preliminary high-level classification can be discussed, but a correct scope and overlap analysis requires claim language, family, and legal status.
References (APA)
No sources were provided in the prompt, and no verifiable bibliographic or claim text for JP2019199485 is included in the input.
